Amenorreia induzida por ciclofosfamida em doentes pré-menopausicas com Lúpus Eritematoso Sistémico

Detalhes bibliográficos
Autor(a) principal: Cunha, I
Data de Publicação: 2008
Outros Autores: Saavedra, MJ, Pereira da Silva, JA, Malcata, AB
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.4/329
Resumo: OBJECTIVES: To determine the frequency of ovarian failure in pre-menopausal women after cyclophosphamide (cyc) treatment for systemic lupus erythematosus (SLE); identify risk factors for this complication; estimate the occurrence and viability of pregnancy during and after treatment. METHODS: Review of the data of women treated with intravenous cyc in the department of Rheumatology of Hospitais da Universidade de Coimbra, updated by interview. Information on demographic features; gynaecologic and obstetrical history; characteristics of the disease; duration and side effects of treatment were obtained. Ovarian failure was defined as a lack of menses for, at least, four months and the diagnosis was confirmed by hormonal measurements. RESULTS: Nineteen pre-menopausal women were treated with intravenous cyc in our department. The mean age at the time of cyc initiation was 28.4 years. Lupus nephritis was the most common indication for cyc treatment (89.5%). The mean number of pulses was 9.3 over a period of 16.8 months. The mean cumulative dosage was 6.973 mg. Three patients developed ovarian failure. Those women were older than the others (P=0.0016). One patient became pregnant while on treatment. Two women delivered healthy children after cyc withdrawal. CONCLUSION: Ovarian failure developed in 15.8% of our patients. As described in the literature, the age at cyc initiation appears to be a determinant risk factor. Pregnancy may occur during cyc therapy, and thus, an effective contraception is mandatory. After cyc withdrawal, pregnancy is possible with a favourable outcome.
id RCAP_aef607c184a09e4ba8ceda7252470e63
oai_identifier_str oai:rihuc.huc.min-saude.pt:10400.4/329
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Amenorreia induzida por ciclofosfamida em doentes pré-menopausicas com Lúpus Eritematoso SistémicoCyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosusAmenorreiaCiclofosfamidaLúpus Eritematoso SistémicoOBJECTIVES: To determine the frequency of ovarian failure in pre-menopausal women after cyclophosphamide (cyc) treatment for systemic lupus erythematosus (SLE); identify risk factors for this complication; estimate the occurrence and viability of pregnancy during and after treatment. METHODS: Review of the data of women treated with intravenous cyc in the department of Rheumatology of Hospitais da Universidade de Coimbra, updated by interview. Information on demographic features; gynaecologic and obstetrical history; characteristics of the disease; duration and side effects of treatment were obtained. Ovarian failure was defined as a lack of menses for, at least, four months and the diagnosis was confirmed by hormonal measurements. RESULTS: Nineteen pre-menopausal women were treated with intravenous cyc in our department. The mean age at the time of cyc initiation was 28.4 years. Lupus nephritis was the most common indication for cyc treatment (89.5%). The mean number of pulses was 9.3 over a period of 16.8 months. The mean cumulative dosage was 6.973 mg. Three patients developed ovarian failure. Those women were older than the others (P=0.0016). One patient became pregnant while on treatment. Two women delivered healthy children after cyc withdrawal. CONCLUSION: Ovarian failure developed in 15.8% of our patients. As described in the literature, the age at cyc initiation appears to be a determinant risk factor. Pregnancy may occur during cyc therapy, and thus, an effective contraception is mandatory. After cyc withdrawal, pregnancy is possible with a favourable outcome.Sociedade Portuguesa de ReumatologiaRIHUCCunha, ISaavedra, MJPereira da Silva, JAMalcata, AB2008-12-11T16:30:10Z20082008-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.4/329porActa Reumatol Port. 2008 Jan-Mar;33(1):69-76info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-11T14:21:28Zoai:rihuc.huc.min-saude.pt:10400.4/329Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:03:08.357800Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Amenorreia induzida por ciclofosfamida em doentes pré-menopausicas com Lúpus Eritematoso Sistémico
Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus
title Amenorreia induzida por ciclofosfamida em doentes pré-menopausicas com Lúpus Eritematoso Sistémico
spellingShingle Amenorreia induzida por ciclofosfamida em doentes pré-menopausicas com Lúpus Eritematoso Sistémico
Cunha, I
Amenorreia
Ciclofosfamida
Lúpus Eritematoso Sistémico
title_short Amenorreia induzida por ciclofosfamida em doentes pré-menopausicas com Lúpus Eritematoso Sistémico
title_full Amenorreia induzida por ciclofosfamida em doentes pré-menopausicas com Lúpus Eritematoso Sistémico
title_fullStr Amenorreia induzida por ciclofosfamida em doentes pré-menopausicas com Lúpus Eritematoso Sistémico
title_full_unstemmed Amenorreia induzida por ciclofosfamida em doentes pré-menopausicas com Lúpus Eritematoso Sistémico
title_sort Amenorreia induzida por ciclofosfamida em doentes pré-menopausicas com Lúpus Eritematoso Sistémico
author Cunha, I
author_facet Cunha, I
Saavedra, MJ
Pereira da Silva, JA
Malcata, AB
author_role author
author2 Saavedra, MJ
Pereira da Silva, JA
Malcata, AB
author2_role author
author
author
dc.contributor.none.fl_str_mv RIHUC
dc.contributor.author.fl_str_mv Cunha, I
Saavedra, MJ
Pereira da Silva, JA
Malcata, AB
dc.subject.por.fl_str_mv Amenorreia
Ciclofosfamida
Lúpus Eritematoso Sistémico
topic Amenorreia
Ciclofosfamida
Lúpus Eritematoso Sistémico
description OBJECTIVES: To determine the frequency of ovarian failure in pre-menopausal women after cyclophosphamide (cyc) treatment for systemic lupus erythematosus (SLE); identify risk factors for this complication; estimate the occurrence and viability of pregnancy during and after treatment. METHODS: Review of the data of women treated with intravenous cyc in the department of Rheumatology of Hospitais da Universidade de Coimbra, updated by interview. Information on demographic features; gynaecologic and obstetrical history; characteristics of the disease; duration and side effects of treatment were obtained. Ovarian failure was defined as a lack of menses for, at least, four months and the diagnosis was confirmed by hormonal measurements. RESULTS: Nineteen pre-menopausal women were treated with intravenous cyc in our department. The mean age at the time of cyc initiation was 28.4 years. Lupus nephritis was the most common indication for cyc treatment (89.5%). The mean number of pulses was 9.3 over a period of 16.8 months. The mean cumulative dosage was 6.973 mg. Three patients developed ovarian failure. Those women were older than the others (P=0.0016). One patient became pregnant while on treatment. Two women delivered healthy children after cyc withdrawal. CONCLUSION: Ovarian failure developed in 15.8% of our patients. As described in the literature, the age at cyc initiation appears to be a determinant risk factor. Pregnancy may occur during cyc therapy, and thus, an effective contraception is mandatory. After cyc withdrawal, pregnancy is possible with a favourable outcome.
publishDate 2008
dc.date.none.fl_str_mv 2008-12-11T16:30:10Z
2008
2008-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.4/329
url http://hdl.handle.net/10400.4/329
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Acta Reumatol Port. 2008 Jan-Mar;33(1):69-76
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Reumatologia
publisher.none.fl_str_mv Sociedade Portuguesa de Reumatologia
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131696199630848